Quick Answer
AYTU BIOPHARMA, INC reported Revenue (ASC 606) of $66.38 million for fiscal year 2025.
AYTU BIOPHARMA, INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $66.38M | +1.8% |
| 2024 | $65.18M | -39.3% |
| 2023 | $107.40M | +11.1% |
| 2022 | $96.67M | +47.3% |
| 2021 | $65.63M | +137.5% |
| 2020 | $27.63M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $15.16M | -6.5% | +9.2% |
| September 30, 2025 | $13.89M | -16.2% | -24.7% |
| March 31, 2025 | $18.45M | +31.6% | +13.8% |
| December 31, 2024 | $16.22M | -13.5% | -2.1% |
| September 30, 2024 | $16.57M | -7.0% | +18.2% |
| March 31, 2024 | $14.03M | -38.3% | -25.2% |
| December 31, 2023 | $18.75M | -28.7% | +5.2% |
| September 30, 2023 | $17.82M | -35.6% | -21.6% |
- AYTU BIOPHARMA, INC showed an increase of +1.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, AYTU BIOPHARMA, INC’s revenue (asc 606) has grown by 140.2% (from $27.63 million to $66.38 million).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: